Lymphocyte-activation gene-3, an important immune checkpoint in cancer

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

LAG3 Expression in Active Mycobacterium tuberculosis Infections

(2015) Bonnie L. Phillips et al.   AMERICAN JOURNAL OF PATHOLOGY

Lymphocyte activation gene 3 negatively regulates the function of intrahepatic hepatitis C virus-specific CD8+T cells

(2015) Na Chen et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

The Upregulation of LAG-3 on T Cells Defines a Subpopulation with Functional Exhaustion and Correlates with Disease Progression in HIV-Infected Subjects

(2015) Xiaoling Tian et al.   JOURNAL OF IMMUNOLOGY

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Elevated expression of LAG-3, but not PD-1, is associated with impaired iNKT cytokine production during chronic HIV-1 infection and treatment

(2015) Jennifer A Juno et al.   Retrovirology

Alternative Activation of Human Plasmacytoid DCs In Vitro and in Melanoma Lesions: Involvement of LAG-3

(2014) Chiara Camisaschi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Role of Lymphocyte Activation Gene-3 (Lag-3) in Conventional and Regulatory T Cell Function in Allogeneic Transplantation

(2014) Emanuela I. Sega et al.   PLoS One

Lymphocyte Activation Gene-3 Expression Defines a Discrete Subset of HIV-Specific CD8+ T Cells That Is Associated with Lower Viral Load

(2013) José Peña et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells

(2013) Nicola Gagliani et al.   NATURE MEDICINE

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer Immunotherapy

(2013) J. Couzin-Frankel   SCIENCE

Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8+ T cell in HCC patients

(2012) Fu-Jun Li et al.   IMMUNOLOGY LETTERS

Construction, and In Vitro and In Vivo Analyses of Tetravalent Immunoadhesins

(2012) Hoonsik Cho   JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

LAG-3, TGF- , and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L

(2011) C. L. Lucas et al.   BLOOD

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

(2011) S.-R. Woo et al.   CANCER RESEARCH

PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice

(2011) Taku Okazaki et al.   JOURNAL OF EXPERIMENTAL MEDICINE

MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis

(2011) P. Hemon et al.   JOURNAL OF IMMUNOLOGY

Cutting Edge: Accelerated Autoimmune Diabetes in the Absence of LAG-3

(2011) M. Bettini et al.   JOURNAL OF IMMUNOLOGY

Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection

(2011) Noah S Butler et al.   NATURE IMMUNOLOGY

Common single nucleotide polymorphisms in immunoregulatory genes and multiple myeloma risk among women in Connecticut

(2010) Kyoung-Mu Lee et al.   AMERICAN JOURNAL OF HEMATOLOGY

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

LAG-3 Expression Defines a Subset of CD4+CD25highFoxp3+ Regulatory T Cells That Are Expanded at Tumor Sites

(2010) C. Camisaschi et al.   JOURNAL OF IMMUNOLOGY

High Expression of Lymphocyte-Activation Gene 3 (LAG3) in Chronic Lymphocytic Leukemia Cells Is Associated with Unmutated Immunoglobulin Variable Heavy Chain Region (IGHV) Gene and Reduced Treatment-Free Survival

(2010) Jana Kotaskova et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Tumor-infiltrating NY-ESO-1–specific CD8+T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

(2010) Junko Matsuzaki et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

On the role of the inhibitory receptor LAG-3 in acute and chronic LCMV infection

(2009) Kirsten Richter et al.   INTERNATIONAL IMMUNOLOGY

Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells

(2009) J. F. Grosso et al.   JOURNAL OF IMMUNOLOGY

LAG-3 Regulates Plasmacytoid Dendritic Cell Homeostasis

(2009) C. J. Workman et al.   JOURNAL OF IMMUNOLOGY

Molecular cloning and expression analysis of pig lymphocyte activation gene-3 (LAG-3; CD223)

(2009) Seon-Soo Kim et al.   VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection

(2008) Shawn D Blackburn et al.   NATURE IMMUNOLOGY